Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study will test the effect of dopamine, serotonin, and direct 5-HT2A receptor stimulation on empathy, mood perception, and amygdala activity to fearful stimuli. In addition, we predict associations between subjective effects/alterations in emotion processing tests and functional imaging (fMRI) activity.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo, LSD, d-Amphetamine, MDMA | Other | Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase |
|
| LSD, d-Amphetamine, MDMA, Placebo | Other | Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase |
|
| d-Amphetamine, MDMA, LSD, Placebo | Other | Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase |
|
| MDMA, LSD, Placebo, d-Amphetamine,, | Other | Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LSD | Drug | 100ug per os, single dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Emotional enhancement as determined by fMRI | Emotional enhancement (empathy, oxytocin, mood perception, fMRI amygdala blood oxygen level-dependent (BOLD) signal reactivity to fearful stimuli) | 12 hours |
| fMRI brain activity | Associations between subjective effects/alterations in emotion processing with fMRI amygdala BOLD activity | 1 hour |
| Measure | Description | Time Frame |
|---|---|---|
| Resting State fMRI | Association between emotional enhancement and resting state fMRI neuronal activity | 1 hour |
| Effect Modulation by personality traits (assessed with questionnaires), | Effect modulation by personality traits (assessed with questionnaires), baseline amygdala reactivity to fear in the fMRI, and genetic polymorphisms determined by genotyping of each subject |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Matthias E Liechti, MD, MAS | University Hospital, Basel, Switzerland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Basel | Basel | Canton of Basel-City | 4031 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008238 | Lysergic Acid Diethylamide |
| D018817 | N-Methyl-3,4-methylenedioxyamphetamine |
| D000661 | Amphetamine |
| D003913 | Dextroamphetamine |
| ID | Term |
|---|---|
| D008237 | Lysergic Acid |
| D004873 | Ergolines |
| D004876 | Ergot Alkaloids |
| D000470 | Alkaloids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| MDMA | Drug | 125mg per os, single dose |
|
|
| Amphetamine | Drug | 40.3mg per os, single dose |
|
|
| Placebo | Drug | Capsules containing mannitol looking identical to the other drugs |
|
| 12 hours |
| Effect Modulation by amygdala reactivity to fear (assessed in the fMRI) | Effect modulation by personality traits (assessed with questionnaires), baseline amygdala reactivity to fear in the fMRI, and genetic polymorphisms determined by genotyping of each subject | 12 hours |
| Effect Modulation by genetic polymorphisms (determined by genotyping of each subject) | Effect modulation by personality traits (assessed with questionnaires), baseline amygdala reactivity to fear in the fMRI, and genetic polymorphisms determined by genotyping of each subject | 12 hours |
| D006571 |
| Heterocyclic Compounds |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D000662 | Amphetamines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |